All Stories

  1. Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients (the GALACTBAS study)
  2. Breakthrough Mold Infections During Long-term Nebulized Liposomal Amphotericin B Prophylaxis in Lung Transplant Recipients: A Single-center Cohort (NEBULA Study)
  3. Urinary tract infection: From evidence to clinical practice
  4. Liver abscesses in Southern Europe: clinical and microbiological characterization of a retrospective cohort
  5. Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report
  6. Combined serum (1,3)-β-D-Glucan and Oral Wash PCR as a non-invasive diagnostic strategy for early detection of Pneumocystis jirovecii pneumonia: an observational retrospective study
  7. Tuberculosis incidence in solid organ transplant recipients in Europe: A multicenter TBnet cohort study
  8. Implementing CLIA for QuantiFERON®-CMV testing: Optimizing cellular immune response against cytomegalovirus
  9. A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation
  10. Utility of the ELISpot Test to Predict the Risk of Developing BK Polyomavirus Nephropathy in Kidney Recipients, a Multicenter Study
  11. Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC/SEIMC, CIBERINFEC, and SET recommendations update.
  12. ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in solid organ transplant recipients
  13. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874
  14. Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update
  15. Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria
  16. Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation
  17. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
  18. Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis
  19. Tobramycin Systemic Absorption in Lung Transplant Recipients Treated With Inhaled Tobramycin: A Cohort Study
  20. Effect of SARS‐CoV‐2 preventive measures on early lung transplant fungal acquisition: An observational study
  21. Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SA...
  22. Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant Enterobacterales
  23. Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period
  24. Transplantation of organs from SARS‐CoV‐2‐positive donors: Preliminary experience from Spain
  25. Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study
  26. Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy
  27. Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
  28. Preliminary Clinical Experience of Molnupiravir to Prevent Progression of COVID-19 in Kidney Transplant Recipients
  29. Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection
  30. Nosocomial COVID-19. Prospective study in a referral hospital
  31. COVID-19 nosocomial. Estudio prospectivo en un hospital de referencia
  32. Positive Polymerase Chain Reaction for SARS-CoV-2 in a Candidate Does Not Always Preclude Liver Transplantation: Case Report and Literature Review
  33. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)
  34. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)
  35. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  36. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  37. Low seroprevalence of SARS‐CoV‐2 antibodies in a liver transplant cohort
  38. Long‐term effects of COVID‐19 in solid organ transplantation recipients
  39. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial
  40. Nebulized Micafungin Treatment for Scopulariopsis / Microascus Tracheobronchitis in Lung Transplant Recipients
  41. Does Routine Abdominal Drain Tip Culture Anticipate Post-Operative Infection in Liver Transplantation?
  42. CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients
  43. COVID‐19 in lung transplant recipients: A multicenter study
  44. Executive summary of the Consensus Statement of the Transplant Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the National Transplant Organization (ONT) on the Selection Criteria of D...
  45. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
  46. COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management
  47. Routine Bile Culture From Liver Donors as Screening of Donor‐Transmitted Infections in Liver Transplantation
  48. A new pleosporalean fungus isolated from superficial to deep human clinical specimens
  49. Nuevos antibióticos para el tratamiento de las infecciones por microorganismos multirresistentes
  50. Selection criteria of solid organ donors in relation to infectious diseases: A Spanish consensus
  51. An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia
  52. Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance
  53. Riesgo de infección asociado a nuevas terapias para el tratamiento de los síndromes linfoproliferativos
  54. Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane
  55. Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial
  56. Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: Report of two cases and comprehensive review of the literature
  57. Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended spectrum beta-lactamase: can they be treated successfully with cephalosporins?
  58. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®
  59. Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study
  60. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam
  61. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction
  62. Clinical Characteristics and Outcome of Lung Transplant Recipients with Respiratory Isolation ofCorynebacteriumspp.
  63. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
  64. Prevalence of Chagas Disease among Solid Organ–Transplanted Patients in a Nonendemic Country
  65. Case Report: Successful Lung Transplantation from a Donor Seropositive for Trypanosoma cruzi Infection (Chagas Disease) to a Seronegative Recipient
  66. Successful liver transplantation despite donor-transmitted ESBL-producing Klebsiella pneumoniae infection: Case report and review of the literature
  67. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
  68. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
  69. Reply to “Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin”
  70. Determination of neutrophil CD64 expression as a prognostic biomarker in patients with community-acquired pneumonia
  71. Fosfomycin for Recurrent Campylobacter
  72. Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis
  73. Epidemiology and Diagnosis of Tuberculous Lymphadenitis
  74. Reply
  75. A 72-Year-Old Man With Dyspnea, Circumferential Aortic Thickening, and Weight Loss